

# Assay Guidance Workshop for High-Throughput Screening and Lead Discovery

Tuesday Sept 24, 2024 – Wednesday Sept 25, 2024  
1 Lilly Corporate Ctr, Indianapolis, IN 46285

## AGENDA: Day 1

- 10:00 AM **The NCATS Assay Guidance Manual Program: Advancing the Practice and Rigor of Preclinical Translation**  
Sarine Markossian, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
- 10:15 AM **Session 1: Target ID/Validation and Assay Development**
- 10:15 AM **Target Identification and Validation**  
Matt Chang, Loxo, San Francisco
- 11:00 AM **Strategies for Assay Selection and for the Development of Robust Biochemical Assays**  
Nathan Coussens, Frederick National Laboratory for Cancer Research
- 11:45 AM **Treating Cells as Reagents and Measuring Viable, Dead, or Apoptotic Cell Number as Orthogonal Controls to Design Reproducible Assays**  
Terry Riss, Promega Corporation
- 12:30 PM **Lunch Break**
- 1:30 PM **Session 2: HTS Assay Interpretation, Statistics and Data Analysis**
- 1:30 PM **Assay Interpretation: Studies in Mechanisms and Methods in Assay Interferences**  
Douglas Auld, Novartis Institutes for BioMedical Research
- 2:15 PM **Basic Assay Statistics, Data Analysis & Rules of Thumb (ROT)**  
Thomas Chung, Sanford Burnham Prebys Medical Discovery Institute
- 3:00 PM **Break**
- 3:30 PM **Session 2: (continued)**
- 3:30 PM **Reproducibility Assessment of *In Vitro* Screening Results**  
Philip Iversen, Luther College
- 4:15 PM **AGM Webtools Hands-on Training**  
Philip Iversen, Luther College  
Jason Manro, Eli Lilly and Company  
Jeffrey Weidner, QualSci Consulting
- 5:00 PM **Adjourn**

## AGENDA: Day 2

8:30 AM – 9:30 AM	<b>Tour of Eli Lilly Facilities</b>
9:50 AM	<b>Welcome and Today's Agenda</b> Sarine Markossian, NCATS, NIH
10:00 AM	<b>Session 3: Biophysical Approaches</b>
10:00 AM	<b>Small Molecule Discovery and Target Interaction Validation Using Biophysical Techniques</b> Michael Ronzetti, NCATS
10:45 AM	<b>Introduction to Mass Spectrometry for Drug Screening and Lead Optimization</b> Mackenzie Pearson, Eli Lilly and Company
11:30 AM	<b>Session 4: Lead Optimization</b>
11:30 AM	<b><i>In Vitro</i> Assessments of ADME Properties of Lead Compounds</b> Mike Mohutsky, Eli Lilly and Company
12:15 PM	<b>Lunch Break</b>
1:15 PM	<b>Session 4: (continued)</b>
1:15 PM	<b>PK/PD Concepts for <i>in vitro</i>/ <i>in vivo</i> Assays</b> Maria Posada, Eli Lilly and Company
2:00 PM	<b>Session 5: New Modalities and Novel Trends</b>
2:00 PM	<b>ADC Assay Development and Design, Best Practices</b> Carmen Perez, Eli Lilly and Company
2:45 PM	<b>Break</b>
3:15 PM	<b>Session 5: (continued)</b>
3:15 PM	<b>Drug Screening with Engineered 3D Tissue Models</b> Marc Ferrer, NCATS, NIH
4:00 PM	<b>Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries</b> Timothy Foley, Pfizer
4:45 PM	<b>Open discussion and additional Q&amp;A</b>
5:00 PM	<b>Adjourn</b>